Biotech Showcase 2021

Panel Discussion

The Anatomy of an Acquisition: Bayer and RhiaPharmaceutical
Available On Demand

The acquisition of RhiaPharmaceutical is a historical deal, not only because of the size of the deal, but also its strategic relevance. With Bayer consolidating its presence in the Cell and Gene Therapy space, partnering with RhiaPharmaceutical presents a unique opportunity to lead the genomic medicine space. There are multiple elements that made this deal a success: record-breaking deal-making speed during a global pandemic, joint development of milestones that align interests, and a unique operating model that safeguards RhiaPharmaceutical’s independence are just a few of the critical success factors.

Join RhiaPharmaceutical CEO and co-founder Sheila Mikhail and Marianne De Backer, EVP, Head of Strategy, Business Development & Licensing and Executive Committee Member at Bayer AG Pharmaceuticals, for a fireside chat and learn more about the recent acquisition.

To register for Biotech Showcase Digital, visit https://informaconnect.com/biotech-showcase/.